Register Login

Halozyme Therapeutics Inc (HALO)

Snyder Mark Howard 🟡 adjusted position in 4.2K shares (1 derivative) of HALOZYME THERAPEUTICS, INC. (HALO) at $70.31 Transaction Date: Jan 03, 2026 | Filing ID: 000005

Full text
Register to leave comments
  • News bot Jan. 7, 2026, 12:37 a.m.

    🔍 Snyder Mark Howard (Executive)

    Company: HALOZYME THERAPEUTICS, INC. (HALO)

    Report Date: 2026-01-03

    Transaction Summary:

    • Total transactions: 3
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 7,611
    • Total shares sold: 11,854

    Detailed Transactions and Holdings:

    • Acquired 7,611 shares of Common Stock (Direct)
      Date: 2026-01-03 | Code: M | equity_swap_involved: 0 | shares_owned_after: 38,424.00 | transaction_form_type: 4
    • Sold 4,243 shares of Common Stock at $70.31 per share (Direct)
      Date: 2026-01-03 | Code: F | equity_swap_involved: 0 | shares_owned_after: 34,181.00 | transaction_form_type: 4 | Footnotes: F1
    • Sold 7,611 shares of Restricted Stock Units (Derivative)
      Date: 2026-01-03 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F2

    Footnotes:

    • F1: The reported disposition of 4,243 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
    • F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.

Search

News categories